Latest Ratios: P/E Ratio -79.5x · EV/EBITDA 15.4x · ROE -4.3%. (1998–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $11.1B | $10.1B | $9.6B | $12.2B | $11.2B | $19.4B | $12.6B | $7.6B | $5.5B | $5.3B | $3.7B |
| Enterprise Value | $14.0B | $12.9B | $12.1B | $15.0B | $14.0B | $22.3B | $14.6B | $9.4B | $7.0B | $6.3B | $4.8B |
| P/E Ratio → | -79.53 | — | 930.80 | 25.64 | 22.99 | 49.58 | 34.70 | 30.13 | 24.50 | 43.09 | 23.59 |
| P/S Ratio | 2.78 | 2.51 | 2.37 | 2.95 | 2.81 | 5.47 | 4.32 | 2.90 | 2.45 | 2.86 | 2.17 |
| P/B Ratio | 3.57 | 3.14 | 2.74 | 3.32 | 3.70 | 7.48 | 5.90 | 4.56 | 4.15 | 5.00 | 4.28 |
| P/FCF | 21.50 | 19.47 | 19.16 | 33.29 | 37.91 | 36.42 | 33.28 | 22.30 | 18.43 | 22.73 | 15.03 |
| P/OCF | 15.11 | 13.68 | 13.08 | 17.78 | 18.04 | 25.47 | 23.14 | 15.78 | 12.58 | 16.81 | 12.25 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.22 | 3.00 | 3.62 | 3.53 | 6.31 | 4.99 | 3.58 | 3.11 | 3.39 | 2.84 |
| EV / EBITDA | 15.36 | 14.21 | 20.61 | 16.05 | 14.71 | 26.12 | 21.83 | 17.07 | 14.29 | 15.01 | 13.10 |
| EV / EBIT | 27.57 | 25.49 | 55.33 | 20.83 | 20.58 | 40.28 | 27.32 | 25.70 | 20.41 | 19.27 | 19.04 |
| EV / FCF | — | 24.97 | 24.20 | 40.92 | 47.61 | 41.99 | 38.36 | 27.55 | 23.41 | 26.93 | 19.63 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.5% | 30.5% | 32.9% | 36.4% | 36.8% | 37.7% | 36.7% | 36.6% | 37.1% | 37.7% | 38.3% |
| Operating Margin | 12.6% | 12.6% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% |
| Net Profit Margin | -3.6% | -3.6% | 0.3% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -4.3% | -4.3% | 0.3% | 14.2% | 17.3% | 16.5% | 19.1% | 16.8% | 18.8% | 12.9% | 19.1% |
| ROA | -2.0% | -2.0% | 0.1% | 6.0% | 6.6% | 6.2% | 7.2% | 5.9% | 6.7% | 4.4% | 6.5% |
| ROIC | 6.3% | 6.3% | 2.7% | 7.5% | 8.5% | 9.2% | 8.6% | 8.4% | 10.2% | 10.8% | 10.2% |
| ROCE | 8.1% | 8.1% | 3.3% | 9.0% | 10.4% | 11.1% | 10.0% | 9.6% | 11.5% | 12.1% | 11.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.95 | 0.95 | 0.78 | 0.84 | 1.02 | 1.24 | 1.01 | 1.22 | 1.27 | 1.08 | 1.45 |
| Debt / EBITDA | 3.36 | 3.36 | 4.62 | 3.29 | 3.24 | 3.75 | 3.24 | 3.69 | 3.44 | 2.73 | 3.39 |
| Net Debt / Equity | — | 0.89 | 0.72 | 0.76 | 0.95 | 1.14 | 0.90 | 1.07 | 1.12 | 0.92 | 1.31 |
| Net Debt / EBITDA | 3.13 | 3.13 | 4.29 | 3.00 | 3.00 | 3.47 | 2.89 | 3.25 | 3.05 | 2.34 | 3.07 |
| Debt / FCF | — | 5.50 | 5.04 | 7.64 | 9.71 | 5.57 | 5.08 | 5.25 | 4.99 | 4.20 | 4.60 |
| Interest Coverage | 4.74 | 4.74 | 1.74 | 5.25 | 11.51 | 7.50 | 6.17 | 5.99 | 5.42 | 10.97 | 9.05 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.29 | 1.29 | 1.41 | 1.52 | 1.32 | 1.23 | 1.43 | 1.44 | 1.61 | 1.78 | 1.53 |
| Quick Ratio | 1.02 | 1.02 | 1.13 | 1.16 | 1.08 | 1.04 | 1.21 | 1.21 | 1.38 | 1.54 | 1.31 |
| Cash Ratio | 0.19 | 0.19 | 0.20 | 0.26 | 0.21 | 0.24 | 0.27 | 0.34 | 0.35 | 0.35 | 0.27 |
| Asset Turnover | — | 0.56 | 0.54 | 0.50 | 0.52 | 0.50 | 0.53 | 0.56 | 0.59 | 0.63 | 0.62 |
| Inventory Turnover | 9.33 | 9.33 | 9.76 | 6.91 | 9.83 | 11.07 | 9.96 | 10.35 | 11.15 | 10.06 | 10.83 |
| Days Sales Outstanding | — | 64.44 | 64.97 | 68.98 | 69.07 | 67.06 | 77.11 | 71.58 | 76.06 | 84.49 | 79.03 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 0.1% | 3.9% | 4.4% | 2.0% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% |
| FCF Yield | 4.7% | 5.1% | 5.2% | 3.0% | 2.6% | 2.7% | 3.0% | 4.5% | 5.4% | 4.4% | 6.7% |
| Buyback Yield | 3.2% | 3.6% | 1.2% | 0.2% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 2.0% | 0.3% |
| Total Shareholder Yield | 3.2% | 3.6% | 1.2% | 0.2% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 2.0% | 0.3% |
| Shares Outstanding | — | $50M | $52M | $51M | $51M | $51M | $51M | $50M | $49M | $49M | $48M |
Biotech funding cycle sensitivity
According to recent market data, CRL trades at a TTM P/E of -74.14, reflecting significant earnings distortion, while its forward P/E of 19.45 suggests that investors are pricing in a recovery that remains contingent upon a stabilization of the broader biopharma R&D funding environment.
The negative TTM P/E highlights the impact of non-recurring charges on the bottom line, rendering traditional earnings-based valuation metrics less reliable for assessing current value. Investors should monitor the forward P/E closely, as it implies an expectation of margin normalization that may be overly optimistic given the current revenue contraction.
Based on reported financial statements, CRL's ROIC has trended downward to 1.5% in 2026Q1, indicating that the company is struggling to generate returns on its invested capital that exceed its cost of capital, a trend exacerbated by recent large-scale acquisitions and operational inefficiencies.
The compression in ROIC suggests that the company's aggressive M&A strategy has yet to yield the expected synergies, potentially leading to capital misallocation. This decline warrants further investigation into whether the current asset base is being utilized effectively or if further impairments are necessary to align book values with economic reality.
As reported in recent filings, CRL's cash conversion cycle has remained elevated at 88 days in 2026Q1, reflecting persistent challenges in managing working capital efficiency compared to historical norms and the broader industry standard for preclinical research service providers.
The extended CCC suggests that the company is facing difficulties in optimizing its inventory and receivables, which may be a byproduct of the complex logistical requirements of its vivarium operations. This inefficiency ties up critical liquidity, limiting the firm's ability to navigate the current cyclical downturn without relying on external financing.
According to quarterly balance sheet data, CRL's debt-to-equity ratio has climbed to 1.02, signaling a shift toward a more leveraged capital structure that may constrain the company's ability to pursue future growth initiatives or weather prolonged periods of negative cash flow.
The increase in leverage, combined with a declining interest coverage ratio of 4.48, suggests that debt service is becoming a more significant burden on the company's cash flow. Investors should monitor whether management prioritizes deleveraging in the coming quarters to restore balance sheet health and reduce financial risk.
The P/E ratio is frequently misapplied to CRL, as it fails to account for the significant non-cash impairment charges and pass-through costs that distort net income, making EV/EBITDA a more appropriate metric for evaluating the company's underlying operational performance and cash-generative capacity.
Relying on P/E obscures the true earning power of the business by focusing on accounting profits that are heavily influenced by non-operating items. Analysts should instead prioritize EV/EBITDA to better understand the core profitability of the DSA and RMS segments, which are less sensitive to the accounting noise inherent in the current income statement.
Includes 30+ ratios · 28 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRL stock.
Charles River Laboratories International, Inc.'s current P/E ratio is -79.5x. The historical average is 27.9x.
Charles River Laboratories International, Inc.'s current EV/EBITDA is 15.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.3x.
Charles River Laboratories International, Inc.'s return on equity (ROE) is -4.3%. The historical average is 7.1%.
Based on historical data, Charles River Laboratories International, Inc. is trading at a P/E of -79.5x. Compare with industry peers and growth rates for a complete picture.
Charles River Laboratories International, Inc. has 30.5% gross margin and 12.6% operating margin. Operating margin between 10-20% is typical for established companies.
Charles River Laboratories International, Inc.'s Debt/EBITDA ratio is 3.4x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.